title: Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity.
abstract: OBJECTIVE
  To compare the prevalence of metabolic syndrome (MetS) and the levels of related biomarkers in patients with psoriatic arthritis (PsA) and psoriasis without arthritis (PsC).
  
  
  METHODS
  This study compared patients with PsA and patients with PsC. The presence of MetS was determined. Serum levels of insulin, adiponectin and leptin were measured. The homeostasis model assessment for insulin resistance (HOMA-IR) was calculated. HOMA-IR, adiponectin and leptin were log-transformed. Continuous variables were compared using the t test and the χ(2) test was used for discrete variables. Multivariate regression models were used to investigate the association of MetS and adiponectin with PsA compared to PsC after adjusting for potential confounding variables.
  
  
  RESULTS
  203 PsA and 155 PsC patients were analysed. The prevalence of MetS was higher in PsA patients compared to those with PsC. However, this did not reach statistical significance (36.5% vs 27.1%, p=0.056). The levels of adipokines were significantly higher in PsA compared to PsC: adiponectin (8.8±5.2 vs 7.4±4.5 log (µg/ml), p=0.009) and leptin in women (3.1±0.8 vs 2.8±0.8, log (ng/ml), p=0.04). HOMA-IR was also higher in PsA (0.97±0.63 vs 0.68±0.81, p<0.001). No difference was observed in leptin levels in men. In multivariate regression analysis, PsA (p=0.04) and the psoriasis area and severity index score (p=0.02) were associated with MetS. Adiponectin was significantly associated with PsA (p=0.005), the use of anti-tumour necrosis factor α therapy (p=0.03) and active joint count (p=0.001).
  
  
  CONCLUSIONS
  MetS and related adipokines correlated with an increased burden of skin and joint inflammation.
authors.affiliation: Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, , Toronto, Ontario, Canada.
authors.forename: Lihi
authors.initials: L
authors.lastname: Eder
authors.forename: Jai
authors.initials: J
authors.lastname: Jayakar
authors.forename: Remy
authors.initials: R
authors.lastname: Pollock
authors.forename: Fawnda
authors.initials: F
authors.lastname: Pellett
authors.forename: Arane
authors.initials: A
authors.lastname: Thavaneswaran
authors.forename: Vinod
authors.initials: V
authors.lastname: Chandran
authors.forename: Cheryl F
authors.initials: CF
authors.lastname: Rosen
authors.forename: Dafna D
authors.initials: DD
authors.lastname: Gladman
mesh_terms: D054392:Adipokines / Q000097:blood*; D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000097:blood / Q000150:complications / Q000188:drug therapy; D015415:Biomarkers / Q000097:blood; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D020738:Leptin / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000209:etiology*; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D054392:Adipokines; D018501:Antirheumatic Agents; D015415:Biomarkers; D007328:Insulin; D020738:Leptin